-
Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster Presentation at EASL Congress 2024
05 Jun 2024 16:00 GMT
… of OCA and bezafibrate. About the Investigational OCA-bezafibrate Combination
Intercept … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator- … the treatment of PBC. OCA-bezafibrate combination therapy is investigational; …
-
Alan Bonder, MD: Phase 2 Data for Combination Obeticholic Acid, Bezafibrate in PBC
28 May 2024 21:46 GMT
… cholestatic liver diseases. The OCA-bezafibrate combination has synergistic mechanisms of … month administration of OCA and bezafibrate has therapeutic potential to … EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY …
-
Q&A: Combination OCA-Bezafibrate for PBC, with Cynthia Levy, MD
23 Nov 2023 19:24 GMT
… of combination OCA and bezafibrate compared to bezafibrate monotherapy on safety, … . The investigational OCA and bezafibrate combination therapy presents an opportunity … Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction …
-
Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction
16 Nov 2023 09:35 GMT
… showed combination obeticholic acid (OCA)-bezafibrate caused normalization of multiple biomarkers … combination of OCA and bezafibrate achieved biochemical remission including … of combination OCA and bezafibrate compared to bezafibrate monotherapy on safety, …
-
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
13 Nov 2023 13:00 GMT
… show combination of OCA + bezafibrate achieved biochemical remission (normalization of … -activated receptor (PPAR) agonist, bezafibrate, on multiple key serum biomarkers … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator- …
-
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
23 Jun 2023 06:45 GMT
… . About the Investigational OCA-bezafibrate Fixed-Dose Combination
Intercept is … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator-activated … the treatment of PBC. OCA-bezafibrate combination therapy is investigational; …
-
Intercept Pharmaceuticals Gets Orphan Drug Status for OCA and Bezafibrate to Treat Primary Biliary Cholangitis
16 May 2023 21:58 GMT
… combination of obeticholic acid and bezafibrate to treat a rare bile … the combination of OCA and bezafibrate, the biopharmaceutical company said.
-
First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis
11 May 2022 14:49 GMT
… of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of …
-
Intercept And Ocaliva In PBC: The Clinical Plan For Bezafibrate
28 Jun 2019 00:10 GMT
… , Intercept announced the acquisition of bezafibrate, a Pan PPAR (α, δ… pruritus in PBC patients. Bezafibrate: The Clinical Plan
Intercept … 3 PBC study of bezafibrate treatment, anti-cholestatic and … market. The addition of bezafibrate to OCA is an …
About
© 1995-2025